VistaGen Therapeutics

New treatments like COMP360, Zuranolone, LY03005, REL-1017, Seltorexant, and ABV-1504 are expected to significantly transform the major depressive disorder (MDD) market. MDD affects 44 million diagnosed cases in the 7MM, with moderate cases being the most prevalent. Treatment approaches include pharmacological interventions, psychotherapy, and lifestyle changes. The market size for MDD is projected to grow from USD 7.1 billion in 2023, driven by disease awareness and new product launches.

Stifel maintains Buy rating on VistaGen Therapeutics with $12.00 price target, citing progress in Phase 3 trials for fasedienol for Social Anxiety Disorder. VistaGen expects top-line data in H2 FY2025, with potential regulatory filing requiring one successful trial. The company's stock trades near cash value, presenting a favorable risk/reward balance. VistaGen's market cap is $68.72M, with stock near 52-week low, but holds more cash than debt, though quickly burning through cash.

Jason McCarthy of Maxim Group maintains a Buy rating on VistaGen Therapeutics (VTGN) with a $12.00 price target, citing successful Phase 3 trials for fasedienol in treating social anxiety disorder and a robust financial position with $97.6 million in cash reserves.